Figures & data
Figure 1. Timeline of regulatory approval of bsAbs with their respective MOA. Linvoseltamab, odronextamab and tarlatamab are currently under regulatory review with a decision anticipated in 2024. Created with Biorender.com.
![Figure 1. Timeline of regulatory approval of bsAbs with their respective MOA. Linvoseltamab, odronextamab and tarlatamab are currently under regulatory review with a decision anticipated in 2024. Created with Biorender.com.](/cms/asset/7a1bd50c-9d95-44d5-99c1-5d4b632c2c8c/kmab_a_2321635_f0001_oc.jpg)
Table 1. Approved bsAbs and bsAbs under regulatory review.
Figure 2. Schematic representation, indication and mechanism of action of approved bsAbs: a) T cell engagers (TCE), b) factor VIII mimetic, dual signaling inhibition: c) bispecific receptor tyrosine kinase (RTK) inhibitor (BsRtki), d) bispecific checkpoint inhibitor (BsCPI), e) dual ligand inhibitor (DLI), f) half-life extended (HLE) ligand inhibitor. Created with Biorender.com.
![Figure 2. Schematic representation, indication and mechanism of action of approved bsAbs: a) T cell engagers (TCE), b) factor VIII mimetic, dual signaling inhibition: c) bispecific receptor tyrosine kinase (RTK) inhibitor (BsRtki), d) bispecific checkpoint inhibitor (BsCPI), e) dual ligand inhibitor (DLI), f) half-life extended (HLE) ligand inhibitor. Created with Biorender.com.](/cms/asset/9e8b5fb3-4b78-42d1-a802-4e7a6fa89f70/kmab_a_2321635_f0002_oc.jpg)